Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
about
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapyPrasugrelPlatelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO studyErosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatmentMRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in micePharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects.Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.The physical association of the P2Y12 receptor with PAR4 regulates arrestin-mediated Akt activation.Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential.Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarctionPlatelet P2 receptors: old and new targets for antithrombotic drugs.Future innovations in anti-platelet therapies.Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures.Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.Effect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study.Prasugrel for the treatment of patients with acute coronary syndrome.Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.Cangrelor: a novel P2Y12 receptor antagonist.Platelet P2Y12 receptor inhibition by thienopyridines: status and future.What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.Review: Antiplatelet drugs: what comes next?P2Y12 receptor in platelet activation.Antiplatelet therapy and vascular disease: an update.Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.TRITON and beyond: new insights into the profile of prasugrel.Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.Modern antiplatelet agents in coronary artery disease.Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal usePopulation Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention.Prasugrel hydrochloride for the treatment of sickle cell disease.A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.Antiplatelet therapy: current strategies and future trends.
P2860
Q24629255-1480AAAC-BC51-4F63-91F0-747A85C5EFB6Q28210429-FF37CFA3-D16B-4779-9693-0A1CC297459EQ28218790-C1F524AA-1A80-4149-814F-18885CFDC913Q28534529-F314E7E5-0F6F-44AA-9928-BCD7DCD500CAQ33225547-094CDC85-0573-4B23-8E52-6F02E2152130Q33571446-3F78DE62-701F-4A88-9D4C-31F0A0C0ACC6Q33685876-C6D2E880-39B8-4761-A959-7DAB3E066F83Q33742756-22743D30-A75F-4A70-89AD-AB4EC80E0BC3Q33902628-42C7399F-EE28-4A90-8C54-4976D430B48DQ34721174-30C3B2F5-E23C-4D14-8F01-49099064A275Q34771381-94F0821C-9057-44D5-920A-7DC2DDD6ECADQ35130686-443DDEE3-C792-4E98-91C0-E5127262B7B3Q35163180-6DB4159D-A6D7-4DF5-9CFD-921EF19BC613Q36090735-980A07C7-20C6-47FD-A412-D258173743E7Q36691632-8BE04119-57E6-4D45-9F85-AB0FC1EBEE01Q36753593-C4D84AC5-75A1-49A2-8E25-C8C699D31E5EQ36939417-08C55093-0135-4623-9158-D7C9F8E78DB2Q36941850-60FCEDCE-B1A6-44D4-8177-F2CD8B9088AAQ37339517-ACF4FF57-0668-44FC-A216-3817BB0B112AQ37429557-92A79FDE-77DB-461E-BAA3-8E33707F5967Q37479088-ED98A824-83A8-4857-9D83-B8C5540898A6Q37486601-670CAF18-EC46-4A38-82FE-677EDFA430F1Q37551923-B1EC3210-7382-4EE4-84D5-E88A865241B3Q37579228-E270B530-490B-4FEE-95C6-3426BED742B8Q37704842-D01113A0-7394-4950-BCE0-D79463F03771Q37809630-F47C7B0D-65A1-43AB-BCFD-CE10F280419DQ37828158-FDA93E92-7755-41EF-8526-2CC13573B870Q37838100-4BBFFE9D-AABD-4E72-A237-04C74DAAFACFQ37925007-B406B33C-419D-46EC-A1E5-4D2959143B17Q37925009-A2F3EB57-7BA8-45D9-A214-5EC3226A80F4Q37982427-1E11BB61-DCD6-418F-B4B7-B9BBA16A578DQ38063289-FF326925-80FB-4073-A857-DC230BE1D258Q38151563-A53C6D2F-7D28-42BB-96E8-FA69B24D7CD8Q38254245-4AA4027A-9BCA-4780-BB1D-5E7F8C9ADB91Q38542096-C4642FC6-28D8-4AAC-AEF5-2944838019D4Q38746324-29EC78A0-4160-4793-A1B1-9A6FFE201F68Q39262810-09E15F6F-B649-4DFE-B245-738D0A50C4A1Q39340714-63D271AD-7BD3-40A6-9718-EBE200716514Q39989728-75A4CB54-06DF-42E9-8F69-683F57DBA275Q40329892-8D188878-0504-449C-8112-825C687EC116
P2860
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacology of CS-747 (prasug ...... 2 receptor antagonist activity
@ast
Pharmacology of CS-747 (prasug ...... 2 receptor antagonist activity
@en
Pharmacology of CS-747 (prasug ...... 2 receptor antagonist activity
@nl
type
label
Pharmacology of CS-747 (prasug ...... 2 receptor antagonist activity
@ast
Pharmacology of CS-747 (prasug ...... 2 receptor antagonist activity
@en
Pharmacology of CS-747 (prasug ...... 2 receptor antagonist activity
@nl
prefLabel
Pharmacology of CS-747 (prasug ...... 2 receptor antagonist activity
@ast
Pharmacology of CS-747 (prasug ...... 2 receptor antagonist activity
@en
Pharmacology of CS-747 (prasug ...... 2 receptor antagonist activity
@nl
P2093
P3181
P356
P1476
Pharmacology of CS-747 (prasug ...... 2 receptor antagonist activity
@en
P2093
Atsuhiro Sugidachi
Fumitoshi Asai
Joseph A Jakubowski
Yoichi Niitsu
P304
P3181
P356
10.1055/S-2005-869524
P407
P577
2005-04-01T00:00:00Z